• Teladoc Health Reports First Quarter 2023 Results

    ソース: Nasdaq GlobeNewswire / 26 4 2023 15:05:01   America/Chicago

    • First quarter 2023 revenue grows 11% year-over-year to $629.2 million
    • First quarter 2023 net loss of $69.2 million, or $0.42 per share
    • First quarter adjusted EBITDA totaled $52.8 million

    PURCHASE, NY, April 26, 2023 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the first quarter ended March 31, 2023.  

    “Teladoc Health delivered strong first quarter results across all key financial and operating metrics to start the year,” said Jason Gorevic, chief executive officer of Teladoc Health. “With a strong financial position, we are able to fund and invest in innovations and a world-class team of medical professionals as we support leading employers, health plans, hospital systems, and governments around the world. We have solid momentum heading into the rest of the year as the market embraces Teladoc Health’s unified whole person care experience.”

             
    Key Financial Data        
    ($ in thousands, except per share data, unaudited)        
     Quarter Ended  Year over Year
     March 31,  Change
     2023  2022   
    Revenue$629,244  $565,350  11 %
             
    Net loss$(69,228) $(6,674,523) N/M  
    Net loss per share, basic and diluted$(0.42) $(41.58) N/M  
             
    Adjusted EBITDA (1)$52,765  $54,497  (3)%

    N/M – Not meaningful
    See note (1) in the Notes section that follows.

    First Quarter 2023

    Revenue increased 11% to $629.2 million from $565.4 million in first quarter 2022. Access fees revenue grew 12% to $550.9 million and other revenue grew 6% to $78.4 million. U.S. revenues grew 10% to $541.7 million and International revenues grew 18% to $87.6 million.

    Revenue increased 5% to $350.0 million for the Teladoc Health Integrated Care (“Integrated Care”) segment and increased 21% to $279.3 million for the BetterHelp segment in first quarter 2023.

    Net loss totaled $69.2 million, or ($0.42) per share, for first quarter 2023, compared to $6,674.5 million, or ($41.58) per share, for first quarter 2022. Results for first quarter 2023 included stock-based compensation expense of $46.0 million, or ($0.28) per share, restructuring costs of $8.1 million, or ($0.05) per share, primarily related to severance, and amortization of acquired intangibles of $50.3 million, or ($0.31) per share.

    Results for first quarter 2022 primarily included a non-cash goodwill impairment charge of $6,600.0 million, or $(41.11) per share, as well as stock-based compensation expense of $60.4 million, or ($0.38) per share, and amortization of acquired intangibles of $49.9 million, or ($0.31) per share.

    Adjusted EBITDA (1) decreased 3% to $52.8 million, compared to $54.5 million for first quarter 2022. Segment adjusted EBITDA increased 51% to $35.1 million for the Integrated Care segment and decreased 41% to $17.6 million for the BetterHelp segment in first quarter 2023.

    GAAP gross margin, which includes depreciation and amortization, was 67.8% for first quarter 2023, compared to 66.0% for first quarter 2022.

    Adjusted gross margin (1) was 69.8% for first quarter 2023, compared to 66.9% for first quarter 2022.

    Capex and Cash Flow

    Net cash provided by operating activities was $13.2 million in first quarter 2023, compared to net cash used in operating activities of $31.7 million in first quarter 2022. Capitalized expenditures and capitalized software (together, “Capex”) was $45.6 million in first quarter 2023, compared to $30.8 million in first quarter 2022. Free cash flow was a net outflow of $32.5 million in first quarter 2023, also compared to a net outflow of $62.6 million in first quarter 2022.

    Financial Outlook

    Teladoc Health provides an outlook based on current market conditions and expectations and what we know today. Based on what we know today, we believe our outlook ranges provide a reasonable baseline for 2023 financial performance.

    For second quarter 2023, we expect:

      
     2Q 2023 Outlook Range
    Revenue$635 - $660 million
    Adjusted EBITDA$60 - $68 million
    Net loss per share($0.55) - ($0.45)
    U.S. Integrated Care Members (2)84.5 - 85.5 million
      

    For the year ending December 31, 2023, we expect:

      
     Full Year 2023 Outlook Range
    Revenue$2,575 - $2,675 million
    Adjusted EBITDA$285 - $325 million
    Net loss per share($1.70) - ($1.25)
    U.S. Integrated Care Members (2)84 - 86 million

    See note (2) in the Notes section that follows.

    Earnings Conference Call

    The first quarter 2023 earnings conference call and webcast will be held Wednesday, April 26, 2023 at 4:30 p.m. E.T. The conference call can be accessed by dialing 1-833-470-1428 for U.S. participants and using the access code # 517662. For international participants, please visit the following link for global dial-in numbers: https://www.netroadshow.com/events/global-numbers?confId=48865. A live audio webcast will also be available online at http://ir.teladoc.com/news-and-events/events-and-presentations/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

    About Teladoc Health

    Teladoc Health empowers all people everywhere to live their healthiest lives by transforming the healthcare experience. As the world leader in whole-person virtual care, Teladoc Health uses proprietary health signals and personalized interactions to drive better health outcomes across the full continuum of care, at every stage in a person’s health journey. Teladoc Health leverages more than two decades of expertise and data-driven insights to meet the growing virtual care needs of consumers and healthcare professionals. For more information, please visit www.teladochealth.com or follow @TeladocHealth on Twitter.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding future financial or operating results, future numbers of members or clients, litigation outcomes, regulatory developments, market developments, new products and growth strategies, and the effects of any of the foregoing on our future results of operations or financial condition.

    Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) changes in laws and regulations applicable to our business model; (ii) changes in market conditions and receptivity to our services and offerings, including our ability to effectively compete; (iii) results of litigation or regulatory actions; (iv) the loss of one or more key clients or the loss of a significant number of members or BetterHelp paying users; (v) changes in valuations or useful lives of our assets; (vi) changes to our abilities to recruit and retain qualified providers into our network; and (vii) the impact of and risk related to impairment losses with respect to goodwill or other assets. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our SEC reports, including, but not limited to, our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as filed with the SEC.

    Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.


    TELADOC HEALTH, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
    (In thousands, except share and per share data, unaudited)

          
     Quarter Ended March 31,
     2023     2022 
    Revenue$629,244  $565,350 
    Expenses:     
    Cost of revenue (exclusive of depreciation and amortization, which is shown separately below) 190,107   187,025 
    Operating expenses:     
    Advertising and marketing 176,790   133,600 
    Sales 54,490   58,329 
    Technology and development 86,985   87,412 
    General and administrative 114,145   104,923 
    Acquisition, integration, and transformation costs 5,944   4,507 
    Restructuring costs 8,102   0 
    Depreciation and amortization 69,783   58,933 
    Goodwill impairment 0   6,600,000 
    Loss from operations (77,102)  (6,669,379)
    Other income, net (4,907)  (724)
    Interest (income) expense, net (3,648)  5,480 
    Loss before provision for income taxes (68,547)  (6,674,135)
    Provision for income taxes 681   388 
    Net loss$(69,228) $(6,674,523)
          
    Net loss per share, basic and diluted$(0.42) $(41.58)
          
    Weighted-average shares used to compute basic and diluted net loss per share 162,922,691   160,532,301 
            
            

    Stock-based Compensation Summary

    Compensation costs for stock-based awards were classified as follows (in thousands):

          
     Quarter Ended
     March 31,
     2023 2022
    Cost of revenue (exclusive of depreciation and amortization,
    which is shown separately)    		$1,353 $2,196
    Advertising and marketing 3,126  3,711
    Sales 8,075  12,071
    Technology and development 12,729  18,087
    General and administrative 20,755  24,371
    Total stock-based compensation expense (3)$46,038 $60,436

    See note (3) in the Notes section that follows.

    Revenues

             
     Quarter Ended  Year over Year
    ($ thousands)March 31,  Change
     2023 2022  
    Revenue by Type        
    Access fees$550,870 $491,337 12%
    Other 78,374  74,013 6%
    Total Revenue$629,244 $565,350 11%
             
    Revenue by Geography        
    U.S. Revenue$541,662 $491,200 10%
    International Revenue 87,582  74,150 18%
    Total Revenue$629,244 $565,350 11%
             
             

    Summary Operating Metrics

           
     Quarter Ended  Year over Year
    (millions, except revenue per member)March 31,  Change
     2023 2022  
    U.S. Integrated Care Members (2)84.9 79.2 7%
           
    BetterHelp Paying Users (4)0.467 0.382 22%
           
    Chronic Care Program Enrollment (5)1.028 0.913 13%


             
     Quarter Ended  Year over Year
     March 31,  Change
     2023 2022  
    Total Visits 4.9  4.5 8 %
             
    Average Revenue Per U.S. Integrated Care Member (6)$1.39 $1.41 (2)%

    See notes (2), (4), (5), and (6) in the Notes section that follows.

    Operating Results by Segment (see note (7) in the Notes section that follows)

    The following table presents operating results by reportable segment for the periods indicated:

             
     Quarter Ended  Year over Year
    ($ thousands, unaudited)March 31,  Change
     2023 2022  
    Teladoc Health Integrated Care        
    Revenue$349,972 $332,384 5 %
    Adjusted EBITDA$35,127 $23,267 51 %
    Adjusted EBITDA Margin % 10.0% 7.0%304 bps
             
    BetterHelp        
    Therapy Services$275,928 $229,117 20 %
    Other Wellness Services 3,344  1,057 216 %
    Total Revenue$279,272 $230,174 21 %
    Adjusted EBITDA$17,638 $30,098 (41)%
    Adjusted EBITDA Margin % 6.3% 13.1%(676)bps
              
              

    TELADOC HEALTH, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
    (In thousands, unaudited)

          
     Quarter Ended March 31,
     2023  2022 
    Cash flows from operating activities:     
    Net loss$(69,228) $(6,674,523)
    Adjustments to reconcile net loss to net cash flows from operating activities:     
    Goodwill impairment 0   6,600,000 
    Depreciation and amortization 69,783   58,933 
    Depreciation of rental equipment 681   770 
    Amortization of right-of-use assets 3,056   3,173 
    Provision for allowances 9,034   4,591 
    Stock-based compensation 46,038   60,436 
    Deferred income taxes (355)  (2,319)
    Accretion of interest 845   826 
    Other, net (3,522)  0 
    Changes in operating assets and liabilities:     
    Accounts receivable (14,046)  (27,842)
    Prepaid expenses and other current assets (6,165)  (18,993)
    Inventory 10,000   2,023 
    Other assets (9,939)  (6,047)
    Accounts payable (9,132)  492 
    Accrued expenses and other current liabilities 15,452   11,706 
    Accrued compensation (32,265)  (48,819)
    Deferred revenue 5,648   7,479 
    Operating lease liabilities (2,858)  (3,626)
    Other liabilities 129   (7)
    Net cash provided by (used in) operating activities 13,156   (31,747)
    Cash flows from investing activities:     
    Capital expenditures (2,363)  (3,913)
    Capitalized software (43,261)  (26,918)
    Other, net 0   3,264 
    Net cash used in investing activities (45,624)  (27,567)
    Cash flows from financing activities:     
    Net proceeds from the exercise of stock options 296   3,585 
    Proceeds from advances from financing companies 3,375   2,232 
    Payment against advances from financing companies (3,548)  (3,921)
    Proceeds from employee stock purchase plan 2,731   3,680 
    Cash received for withholding taxes on stock-based compensation, net 496   103 
    Other, net 3   (2,863)
    Net cash provided by financing activities 3,353   2,816 
    Net decrease in cash and cash equivalents (29,115)  (56,498)
    Foreign exchange difference (488)  (538)
    Cash and cash equivalents at beginning of the period 918,182   893,480 
    Cash and cash equivalents at end of the period$888,579  $836,444 
          
          

    TELADOC HEALTH, INC.

    CONDENSED CONSOLIDATED BALANCE SHEETS
    (In thousands, except share and per share data, unaudited)

          
     March 31,  December 31,
     2023     2022 
    Assets     
    Current assets:     
    Cash and cash equivalents$888,579  $918,182 
    Accounts receivable, net of allowance for doubtful accounts of $6,106 and $4,324, respectively 215,981   210,554 
    Inventories 45,801   56,342 
    Prepaid expenses and other current assets 136,346   130,310 
    Total current assets 1,286,707   1,315,388 
    Property and equipment, net 29,791   29,641 
    Goodwill 1,073,190   1,073,190 
    Intangible assets, net 1,815,948   1,836,765 
    Operating lease - right-of-use assets 39,518   41,831 
    Other assets 63,993   48,540 
    Total assets$4,309,147  $4,345,355 
    Liabilities and stockholders’ equity     
    Current liabilities:     
    Accounts payable$38,625  $47,690 
    Accrued expenses and other current liabilities 184,642   168,693 
    Accrued compensation 50,900   81,554 
    Deferred revenue-current 95,930   90,457 
    Advances from financing companies 11,247   11,375 
    Total current liabilities 381,344   399,769 
    Other liabilities 1,749   1,618 
    Operating lease liabilities, net of current portion 35,927   38,042 
    Deferred revenue, net of current portion 4,117   3,872 
    Advances from financing companies, net of current portion 8,037   8,082 
    Deferred taxes, net 50,613   50,939 
    Convertible senior notes, net 1,536,134   1,535,288 
    Commitments and contingencies     
    Stockholders’ equity:     
    Common stock, $0.001 par value; 300,000,000 shares authorized; 163,919,394 shares and 162,840,360 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively 164   163 
    Additional paid-in capital 17,409,574   17,358,645 
    Accumulated deficit (15,077,515)  (15,008,287)
    Accumulated other comprehensive loss (40,997)  (42,776)
    Total stockholders’ equity 2,291,226   2,307,745 
    Total liabilities and stockholders’ equity$4,309,147  $4,345,355 
            
            

    Non-GAAP Financial Measures:

    To supplement our financial information presented in accordance with generally accepted accounting principles in the United States (“GAAP”), we use adjusted gross profit, adjusted gross margin, EBITDA, adjusted EBITDA and free cash flow, which are non-GAAP financial measures, to clarify and enhance an understanding of past performance. We believe that the presentation of these financial measures enhances an investor’s understanding of our financial performance. We further believe that these financial measures are useful financial metrics to assess our operating performance and financial and business trends from period-to-period by excluding certain items that we believe are not representative of our core business. We use certain financial measures for business planning purposes and in measuring our performance relative to that of our competitors. We utilize adjusted EBITDA as a key measure of our performance.

    Adjusted gross profit is our total revenue minus our total cost of revenue (exclusive of depreciation and amortization, which is shown separately) and adjusted gross margin is adjusted gross profit as a percentage of our total revenue.

    EBITDA consists of net loss before interest (income) expense, net; other income, net, including foreign exchange gain or loss; provision for income taxes; depreciation and amortization; and goodwill impairment. Adjusted EBITDA consists of net loss before interest (income) expense, net; other income, net, including foreign exchange gain or loss; provision for income taxes; depreciation and amortization; goodwill impairment; stock-based compensation; restructuring costs; and acquisition, integration, and transformation costs.

    Free cash flow is net cash (used in) provided by operating activities less capital expenditures and capitalized software development costs. We believe that free cash flow reflects an additional way of viewing our liquidity that, when viewed together with GAAP results, provides management, investors and other users of our financial information with a more complete understanding of factors and trends affecting our cash flows.

    We believe the above financial measures are commonly used by investors to evaluate our performance and that of our competitors. However, our use of the terms adjusted gross profit, adjusted gross margin, EBITDA, adjusted EBITDA and free cash flow may vary from that of others in our industry. None of adjusted gross profit, adjusted gross margin, EBITDA, adjusted EBITDA nor free cash flow should be considered as an alternative to net loss before provision for income taxes, net loss, net loss per share, net cash from operating activities or any other performance measures derived in accordance with GAAP.

    Adjusted gross profit, adjusted gross margin, EBITDA, adjusted EBITDA and free cash flow have important limitations as analytical tools and you should not consider them in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are:

    • adjusted gross margin has been and will continue to be affected by a number of factors, including the fees we charge our clients, the number of visits and cases we complete, the costs paid to providers and medical experts, as well as the costs of our provider network operations center;
    • adjusted gross margin does not reflect the significant depreciation and amortization to cost of revenue;
    • EBITDA and adjusted EBITDA do not reflect goodwill impairment;
    • EBITDA and adjusted EBITDA do not reflect the interest (income) expense, net;
    • EBITDA and adjusted EBITDA eliminate the impact of the provision for income taxes on our results of operations;
    • EBITDA and adjusted EBITDA do not reflect other income, net;
    • adjusted EBITDA does not reflect restructuring costs. Restructuring costs may include certain lease impairment costs, certain losses related to early lease terminations, and severance;
    • adjusted EBITDA does not reflect significant acquisition, integration, and transformation costs. Acquisition, integration and transformation costs include investment banking, financing, legal, accounting, consultancy, integration, fair value changes related to contingent consideration and certain other transaction costs related to mergers and acquisitions. It also includes costs related to certain business transformation initiatives focused on integrating and optimizing various operations and systems, including upgrading our customer relationship management (CRM) and enterprise resource planning (ERP) systems. These transformation cost adjustments made to our results do not represent normal, recurring, operating expenses necessary to operate the business but rather, incremental costs incurred in connection with our acquisition and integration activities;
    • adjusted EBITDA does not reflect the significant non-cash stock compensation expense which should be viewed as a component of recurring operating costs; and
    • other companies in our industry may calculate adjusted gross profit, adjusted gross margin, EBITDA, and adjusted EBITDA differently than we do, limiting the usefulness of these measures as comparative measures.

    In addition, although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and adjusted gross profit, adjusted gross margin, EBITDA and adjusted EBITDA do not reflect any expenditures for such replacements.

    We compensate for these limitations by using adjusted gross profit, adjusted gross margin, EBITDA, adjusted EBITDA, and free cash flow along with other comparative tools, together with GAAP measurements, to assist in the evaluation of operating performance. Such GAAP measurements include net loss, net loss per share, net cash provided by operating activities, and other performance measures.

    In evaluating these financial measures, you should be aware that in the future we may incur expenses similar to those eliminated in this presentation. Our presentation of adjusted gross profit, adjusted gross margin, EBITDA, adjusted EBITDA, and free cash flow should not be construed as an inference that our future results will be unaffected by unusual or nonrecurring items.

    The following is a reconciliation of gross profit and gross margin, the most directly comparable GAAP financial measures, to adjusted gross profit and adjusted gross margin, respectively:

    Reconciliation of GAAP Gross Profit to Adjusted Gross Profit and Adjusted Gross Margin
    (In thousands, unaudited)

           
     Quarter Ended 
     March 31,  
     2023     2022     
    Revenue$629,244  $565,350  
    Cost of revenue (exclusive of depreciation and amortization, which is shown separately below) (190,107)  (187,025) 
    Depreciation and amortization of intangible assets (12,531)  (5,119) 
    Gross Profit 426,606   373,206  
    Depreciation and amortization of intangible assets 12,531   5,119  
    Adjusted gross profit$439,137  $378,325  
           
    Gross margin 67.8 % 66.0 %
    Adjusted gross margin 69.8 % 66.9 %
             

    The following is a reconciliation of net loss, the most directly comparable GAAP financial measure, to EBITDA and adjusted EBITDA:

    Reconciliation of GAAP Net Loss to EBITDA and Adjusted EBITDA
    (In thousands, except for outlook data, unaudited)

                
     Quarter Ended Outlook in millions (8)
     March 31,  Second Quarter Full Year
     2023   2022   2023  2023
    Net loss$(69,228) $(6,674,523) $(90) - (74) $(280) - (206)
    Adjustments:           
    Goodwill impairment 0   6,600,000       
    Other income, net (4,907)  (724)      
    Interest (income) expense, net (3,648)  5,480       
    Provision for income taxes 681   388       
    Depreciation and amortization 69,783   58,933       
    Total Adjustments 61,909   6,664,077       
    Consolidated EBITDA  (7,319)   (10,446)      
    Adjustments:           
    Stock-based compensation 46,038   60,436       
    Acquisition, integration, and transformation costs 5,944   4,507       
    Restructuring costs 8,102   0       
    Total Adjustments 60,084   64,943   134 - 158  491 - 605
    Consolidated Adjusted EBITDA$ 52,765  $ 54,497  $60 - 68 $285 - 325
                
    Segment Adjusted EBITDA           
    Teladoc Health Integrated Care$35,127  $23,267       
    BetterHelp 17,638   30,098       
    Other 0   1,132       
    Consolidated Adjusted EBITDA$ 52,765  $ 54,497       

    See note (8) in the Notes section that follows.

    The following is a reconciliation of net cash provided by (used in) operating activities, the most directly comparable GAAP financial measure, to free cash flow:

    Reconciliation of GAAP Net Cash Provided by (Used in) Operating Activities to Free Cash Flow
    (In thousands, unaudited)

          
     Quarter Ended
     March 31,
     2023  2022 
    Net cash provided by (used in) operating activities$13,156  $(31,747)
    Capital expenditures (2,363)  (3,913)
    Capitalized software (43,261)  (26,918)
    Free Cash Flow$(32,468) $(62,578)
            

    Notes:

    1. A reconciliation of each non-GAAP measure to the most comparable measure under GAAP has been provided in this press release in the accompanying tables. An explanation of these non-GAAP measures is also included under the heading “Non-GAAP Financial Measures.”

    2. U.S. Integrated Care Members represent the number of unique individuals who have paid access and visit fee only access to our suite of integrated care services in the U.S. at the end of the applicable period.

    3. Excluding the amount capitalized related to software development projects.

    4. BetterHelp Paying Users represent the average number of global monthly paying users of our BetterHelp therapy services during the applicable period.

    5. Chronic Care Program Enrollment represents the total of enrollees across our suite of chronic care programs at the end of a given period.

    6. Average revenue per U.S. Integrated Care member is calculated by dividing the total revenue generated from the Integrated Care segment by the average number of U.S. Integrated Care Members (see note 2) during the applicable period.

    7. We have two segments: Teladoc Health Integrated Care (“Integrated Care”) and BetterHelp. The Integrated Care segment includes a suite of global virtual medical services including general medical, expert medical services, specialty medical, chronic condition management, mental health, and enabling technologies and enterprise telehealth solutions for hospitals and health systems. The BetterHelp segment includes virtual therapy and other wellness services provided on a global basis which are predominantly marketed and sold on a direct-to-consumer basis.

      Other includes certain revenues, expenses and charges not related to ongoing segment operations.

    8. We have not provided a full line-item reconciliation for net loss to EBITDA or adjusted EBITDA outlook because we do not provide outlook on the individual reconciling items between net loss, EBITDA, and adjusted EBITDA. This is due to the uncertainty as to timing, and the potential variability, of the individual reconciling items such as impairments, stock-based compensation and the related tax impact, provision for income taxes, acquisition, integration, and transformation costs, and restructuring costs, the effect of which may be significant. Accordingly, a full line-item reconciliation of the GAAP measure to the corresponding non-GAAP financial measure outlook is not available without unreasonable effort.

    Investors:
    Patrick Feeley
    914-265-7925
    IR@teladochealth.com

    Media:
    Chris Stenrud
    860-491-8821
    pr@teladochealth.com


    Primary Logo

シェアする